|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Allergan
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:annualReport
|
https://investors.abbvie.com/financials/annual-reports/default.aspx
|
|
gptkbp:CEO
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:cikNumber
|
1551152
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
00287Y109
|
|
gptkbp:diversityInitiatives
|
yes
|
|
gptkbp:dividendPaying
|
yes
~3.5% (2024)
|
|
gptkbp:ESGReporting
|
yes
|
|
gptkbp:focusArea
|
aesthetics
immunology
neuroscience
oncology
virology
eye care
|
|
gptkbp:foundedBy
|
gptkb:Abbott_Laboratories_(spinoff)
|
|
gptkbp:foundedYear
|
2013
|
|
gptkbp:fullName
|
gptkb:AbbVie_Inc.
|
|
gptkbp:hasChair
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:headquartersLocation
|
gptkb:North_Chicago,_Illinois,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ABBV
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
US00287Y1091
|
|
gptkbp:legalForm
|
gptkb:company
|
|
gptkbp:marketCap
|
over $250 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
gptkb:Fortune_100
|
|
gptkbp:netIncome
|
$4.87 billion (2023)
|
|
gptkbp:notableInvention
|
gptkb:adalimumab_(Humira)
|
|
gptkbp:notableProduct
|
gptkb:Humira
gptkb:Imbruvica
gptkb:Rinvoq
gptkb:Skyrizi
gptkb:Venclexta
|
|
gptkbp:numberOfEmployees
|
2023
~50,000
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:rank
|
gptkb:Fortune_500
gptkb:Forbes_Global_2000
|
|
gptkbp:revenue
|
$54.3 billion (2023)
|
|
gptkbp:SIC
|
2834
|
|
gptkbp:spinOff
|
gptkb:Abbott_Laboratories
|
|
gptkbp:stockSymbol
|
gptkb:NYSE
gptkb:ABBV
|
|
gptkbp:subsidiary
|
gptkb:Allergan
gptkb:Stemcentrx
gptkb:Pharmacyclics
over 30
|
|
gptkbp:tradedOn
|
gptkb:NYSE
|
|
gptkbp:website
|
https://www.abbvie.com/
|
|
gptkbp:bfsParent
|
gptkb:AbbVie
|
|
gptkbp:bfsLayer
|
6
|